Srinivasan Dasarathy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8030466/publications.pdf

Version: 2024-02-01

143 papers 19,255 citations

25034 57 h-index 134 g-index

153 all docs

153 docs citations

153 times ranked 25916 citing authors

#	Article	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
2	Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet, The, 2015, 385, 956-965.	13.7	1,840
3	Alcoholic liver disease. Hepatology, 2010, 51, 307-328.	7.3	981
4	EASL Clinical Practice Guidelines on nutrition in chronic liver disease. Journal of Hepatology, 2019, 70, 172-193.	3.7	608
5	Validity of real time ultrasound in the diagnosis of hepatic steatosis: A prospective study. Journal of Hepatology, 2009, 51, 1061-1067.	3.7	497
6	Sarcopenia from mechanism to diagnosis and treatment in liver disease. Journal of Hepatology, 2016, 65, 1232-1244.	3.7	436
7	Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2011, 60, 404-413.	3.4	433
8	Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. New England Journal of Medicine, 2021, 385, 1559-1569.	27.0	406
9	ESPEN guideline on clinical nutrition in liver disease. Clinical Nutrition, 2019, 38, 485-521.	5.0	387
10	A multicenter study to define sarcopenia in patients with endâ€stage liver disease. Liver Transplantation, 2017, 23, 625-633.	2.4	343
11	Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 156-163.e2.	4.4	322
12	Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 2021, 74, 1611-1644.	7.3	263
13	Fulminant hepatitis in a tropical population: Clinical course, cause, and early predictors of outcome. Hepatology, 1996, 23, 1448-1455.	7.3	244
14	Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. JAMA Network Open, 2019, 2, e1912565.	5.9	230
15	Alcoholic Liver Disease. American Journal of Gastroenterology, 2010, 105, 14-32.	0.4	220
16	Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-κB–mediated mechanism. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18162-18167.	7.1	211
17	Consilience in sarcopenia of cirrhosis. Journal of Cachexia, Sarcopenia and Muscle, 2012, 3, 225-237.	7.3	203
18	Malnutrition in Cirrhosis: Contribution and Consequences of Sarcopenia on Metabolic and Clinical Responses. Clinics in Liver Disease, 2012, 16, 95-131.	2.1	199

#	Article	IF	CITATIONS
19	Late evening snack: Exploiting a period of anabolic opportunity in cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 430-441.	2.8	194
20	The TMAO-Producing Enzyme Flavin-Containing Monooxygenase 3 Regulates Obesity and the Beiging of White Adipose Tissue. Cell Reports, 2017, 19, 2451-2461.	6.4	194
21	Metabolic and molecular responses to leucineâ€enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis. Hepatology, 2015, 61, 2018-2029.	7.3	179
22	Sodium benzoate in the treatment of acute hepatic encephalopathy: A double-blind randomized trial. Hepatology, 1992, 16, 138-144.	7.3	177
23	ESPEN practical guideline: Clinical nutrition in liver disease. Clinical Nutrition, 2020, 39, 3533-3562.	5.0	170
24	Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent. European Journal of Gastroenterology and Hepatology, 2013, 25, 85-93.	1.6	168
25	Ammonia toxicity: from head to toe?. Metabolic Brain Disease, 2017, 32, 529-538.	2.9	166
26	A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation. Hepatology, 2019, 70, 1816-1829.	7.3	163
27	Role of Fresh Frozen Plasma Infusion in Correction of Coagulopathy of Chronic Liver Disease: A Dual Phase Study. American Journal of Gastroenterology, 2003, 98, 1391-1394.	0.4	162
28	Hyperammonemia-mediated autophagy in skeletal muscle contributes to sarcopenia of cirrhosis. American Journal of Physiology - Endocrinology and Metabolism, 2012, 303, E983-E993.	3.5	157
29	Postâ€liver transplantation sarcopenia in cirrhosis: A prospective evaluation. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1250-1257.	2.8	151
30	Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis. Hepatology, 2017, 65, 2045-2058.	7.3	147
31	Sarcopenia and frailty in decompensated cirrhosis. Journal of Hepatology, 2021, 75, S147-S162.	3.7	145
32	Posttransplant metabolic syndrome: An epidemic waiting to happen. Liver Transplantation, 2009, 15, 1662-1670.	2.4	143
33	Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. JAMA - Journal of the American Medical Association, 2021, 326, 2031.	7.4	141
34	Prevalence of Hypothyroidism in Nonalcoholic Fatty Liver Disease. Digestive Diseases and Sciences, 2012, 57, 528-534.	2.3	140
35	Double-blind Randomized Placebo-controlled Clinical Trial of Omega 3 Fatty Acids for the Treatment of Diabetic Patients With Nonalcoholic Steatohepatitis. Journal of Clinical Gastroenterology, 2015, 49, 137-144.	2.2	138
36	Hyperammonaemiaâ€induced skeletal muscle mitochondrial dysfunction results in cataplerosis and oxidative stress. Journal of Physiology, 2016, 594, 7341-7360.	2.9	122

#	Article	IF	CITATIONS
37	Alcohol-induced autophagy contributes to loss in skeletal muscle mass. Autophagy, 2014, 10, 677-690.	9.1	121
38	Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis. European Journal of Gastroenterology and Hepatology, 2011, 23, 382-388.	1.6	112
39	Poor performance of psoas muscle index for identification of patients with higher waitlist mortality risk in cirrhosis. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 1053-1062.	7.3	101
40	Metabolic adaptation of skeletal muscle to hyperammonemia drives the beneficial effects of l-leucine in cirrhosis. Journal of Hepatology, 2016, 65, 929-937.	3.7	96
41	MLKL-dependent signaling regulates autophagic flux in a murine model of non-alcohol-associated fatty liver and steatohepatitis. Journal of Hepatology, 2020, 73, 616-627.	3.7	96
42	Hypovitaminosis D is associated with increased whole body fat mass and greater severity of nonâ€alcoholic fatty liver disease. Liver International, 2014, 34, e118-27.	3.9	94
43	Skeletal muscle atrophy is associated with an increased expression of myostatin and impaired satellite cell function in the portacaval anastamosis rat. American Journal of Physiology - Renal Physiology, 2004, 287, G1124-G1130.	3.4	93
44	Sarcopenia associated with portosystemic shunting is reversed by follistatin. Journal of Hepatology, 2011, 54, 915-921.	3.7	93
45	Posttransplant Sarcopenia: An Underrecognized Early Consequence of Liver Transplantation. Digestive Diseases and Sciences, 2013, 58, 3103-3111.	2.3	92
46	Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis. Journal of Hepatology, 2020, 72, 25-33.	3.7	88
47	Reninâ€angiotensin system and fibrosis in nonâ€alcoholic fatty liver disease. Liver International, 2015, 35, 979-985.	3.9	87
48	Cause and management of muscle wasting in chronic liver disease. Current Opinion in Gastroenterology, 2016, 32, 1.	2.3	84
49	Multicenter Validation of Association Between Decline in MRIâ€PDFF and Histologic Response in NASH. Hepatology, 2020, 72, 1219-1229.	7.3	79
50	Sarcopenia in Alcoholic Liver Disease: Clinical and Molecular Advances. Alcoholism: Clinical and Experimental Research, 2017, 41, 1419-1431.	2.4	73
51	Hyperammonemia and proteostasis in cirrhosis. Current Opinion in Clinical Nutrition and Metabolic Care, 2018, 21, 30-36.	2.5	72
52	Clinical Impact of Alcoholâ€Related Cirrhosis in the Next Decade: Estimates Based on Current Epidemiological Trends in the United States. Alcoholism: Clinical and Experimental Research, 2015, 39, 2085-2094.	2.4	70
53	Biomarkers of Macrophage Activation and Immune Danger Signals Predict Clinical Outcomes in Alcoholic Hepatitis. Hepatology, 2019, 70, 1134-1149.	7.3	66
54	Changes in body composition after transjugular intrahepatic portosystemic stent in cirrhosis: a critical review of literature. Liver International, 2011, 31, 1250-1258.	3.9	65

#	Article	IF	CITATIONS
55	Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. American Journal of Gastroenterology, 2019, 114, 1626-1635.	0.4	65
56	Metabolic and Genomic Response to Dietary Isocaloric Protein Restriction in the Rat. Journal of Biological Chemistry, 2011, 286, 5266-5277.	3.4	64
57	Oxidative stress mediates ethanol-induced skeletal muscle mitochondrial dysfunction and dysregulated protein synthesis and autophagy. Free Radical Biology and Medicine, 2019, 145, 284-299.	2.9	63
58	Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression. Metabolism: Clinical and Experimental, 2021, 116, 154457.	3.4	62
59	Nutrition and Alcoholic Liver Disease. Clinics in Liver Disease, 2016, 20, 535-550.	2.1	60
60	Sarcopenia and a physiologically low respiratory quotient in patients with cirrhosis: a prospective controlled study. Journal of Applied Physiology, 2013, 114, 559-565.	2.5	59
61	Hepatic Mitochondrial Defects in a Nonalcoholic Fatty Liver Disease Mouse Model Are Associated with Increased Degradation of Oxidative Phosphorylation Subunits. Molecular and Cellular Proteomics, 2018, 17, 2371-2386.	3.8	59
62	Altered expression of genes regulating skeletal muscle mass in the portacaval anastamosis rat. American Journal of Physiology - Renal Physiology, 2007, 292, G1105-G1113.	3.4	57
63	Hyperammonemia results in reduced muscle function independent of muscle mass. American Journal of Physiology - Renal Physiology, 2016, 310, G163-G170.	3.4	56
64	Myostatin and beyond in cirrhosis: all roads lead to sarcopenia. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 864-869.	7.3	54
65	Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients. BBA Clinical, 2015, 3, 141-145.	4.1	53
66	Do Handheld Calorimeters Have a Role in Assessment of Nutrition Needs in Hospitalized Patients?. Nutrition in Clinical Practice, 2011, 26, 426-433.	2.4	52
67	Keratin 18 Is a Diagnostic and Prognostic Factor for Acute Alcoholic Hepatitis. Clinical Gastroenterology and Hepatology, 2020, 18, 2046-2054.	4.4	52
68	Relationship between three commonly used nonâ€invasive fibrosis biomarkers and improvement in fibrosis stage in patients with nonâ€alcoholic steatohepatitis. Liver International, 2019, 39, 924-932.	3.9	47
69	Continued muscle loss increases mortality in cirrhosis: Impact of aetiology of liver disease. Liver International, 2020, 40, 1178-1188.	3.9	45
70	Glycine and urea kinetics in nonalcoholic steatohepatitis in human: effect of intralipid infusion. American Journal of Physiology - Renal Physiology, 2009, 297, G567-G575.	3.4	42
71	Diagnosis and management of alcoholic liver disease. Journal of Digestive Diseases, 2011, 12, 257-262.	1.5	42
72	ILâ€1 receptor antagonist plus pentoxifylline and zinc for severe alcoholâ€associated hepatitis. Hepatology, 2022, 76, 1058-1068.	7.3	41

#	Article	IF	Citations
73	Sarcopenia in non-alcoholic fatty liver disease: Targeting the real culprit?. Journal of Hepatology, 2015, 63, 309-311.	3.7	37
74	Presence of sarcopenia (muscle wasting) in patients with nonalcoholic steatohepatitis. Hepatology, 2014, 60, 428-429.	7.3	36
75	Bariatric Surgery in Patients with Cirrhosis and Portal Hypertension. Obesity Surgery, 2018, 28, 3431-3438.	2.1	34
76	Hepatocellular carcinoma in nonalcoholic fatty liver disease with or without cirrhosis: a population-based study. BMC Gastroenterology, 2021, 21, 394.	2.0	32
77	In vitro contraction protects against palmitate-induced insulin resistance in C2C12 myotubes. American Journal of Physiology - Cell Physiology, 2017, 313, C575-C583.	4.6	31
78	Ethanol sensitizes skeletal muscle to ammonia-induced molecular perturbations. Journal of Biological Chemistry, 2019, 294, 7231-7244.	3.4	31
79	Effect of Acid Suppressants on the Risk of COVID-19: A Propensity Score-Matched Study Using UK Biobank. Gastroenterology, 2021, 160, 455-458.e5.	1.3	31
80	Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome. BMJ Open Gastroenterology, 2020, 7, e000352.	2.7	30
81	Handheld Calorimeter Is a Valid Instrument to Quantify Resting Energy Expenditure in Hospitalized Cirrhotic Patients. Nutrition in Clinical Practice, 2012, 27, 677-688.	2.4	28
82	Differential role of MLKL in alcohol-associated and non–alcohol-associated fatty liver diseases in mice and humans. JCI Insight, 2021, 6, .	5.0	27
83	Is the adiponectin-AMPK-mitochondrial axis involved in progression of nonalcoholic fatty liver disease?. Hepatology, 2014, 60, 22-25.	7.3	26
84	Patients with Nonalcoholic Fatty Liver Disease Have a Low Response Rate to Vitamin D Supplementation. Journal of Nutrition, 2017, 147, 1938-1946.	2.9	26
85	HDL flux is higher in patients with nonalcoholic fatty liver disease. American Journal of Physiology - Endocrinology and Metabolism, 2019, 317, E852-E862.	3.5	26
86	Muscle loss contributes to higher morbidity and mortality in <scp>COPD</scp> : An analysis of national trends. Respirology, 2021, 26, 62-71.	2.3	26
87	Inhibition of aromatase improves nutritional status following portacaval anastomosis in male rats. Journal of Hepatology, 2006, 45, 214-220.	3.7	25
88	Reply: Comments on AASLD practice guidelines for alcoholic liver disease. Hepatology, 2010, 51, 1861-1861.	7.3	24
89	Interobserver Variability in Scoring Liver Biopsies with a Diagnosis of Alcoholic Hepatitis. Alcoholism: Clinical and Experimental Research, 2017, 41, 1568-1573.	2.4	24
90	Multiomics-Identified Intervention to Restore Ethanol-Induced Dysregulated Proteostasis and Secondary Sarcopenia in Alcoholic Liver Disease. Cellular Physiology and Biochemistry, 2021, 55, 91-116.	1.6	24

#	Article	IF	CITATIONS
91	Intestinal function is impaired in patients with Chronic Obstructive Pulmonary Disease. Clinical Nutrition, 2021, 40, 2270-2277.	5.0	23
92	Gallbladder Abnormalities in Acute Viral Hepatitis. Journal of Clinical Gastroenterology, 1991, 13, 697-700.	2.2	22
93	Treatment to Improve Nutrition and Functional Capacity Evaluation in Liver Transplant Candidates. Current Treatment Options in Gastroenterology, 2014, 12, 242-255.	0.8	21
94	Safety and efficacy of bariatric surgery in patients with advanced fibrosis. International Journal of Obesity, 2017, 41, 443-449.	3.4	21
95	Gut microbial trimethylamine is elevated in alcohol-associated hepatitis and contributes to ethanol-induced liver injury in mice. ELife, 2022, 11 , .	6.0	21
96	Validation of the accuracy of the FASTâ,,¢ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms. PLoS ONE, 2022, 17, e0266859.	2.5	20
97	The development of a nonâ€invasive model to predict the presence of nonâ€alcoholic steatohepatitis in patients with nonâ€alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 995-1000.	2.8	19
98	Comprehensive metabolic flux analysis to explain skeletal muscle weakness in COPD. Clinical Nutrition, 2020, 39, 3056-3065.	5.0	19
99	Preservation of portal pressure improves growth and metabolic profile in the male portacaval-shunted rat. Digestive Diseases and Sciences, 2002, 47, 1936-1942.	2.3	18
100	Inflammation and Liver. Journal of Parenteral and Enteral Nutrition, 2008, 32, 660-666.	2.6	18
101	Age Impacts Ability of Aspartate–Alanine Aminotransferase Ratio to Predict Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. Digestive Diseases and Sciences, 2015, 60, 1825-1831.	2.3	18
102	Impaired Ribosomal Biogenesis by Noncanonical Degradation of $<$ i> $>$ $\hat{l}^2<$ /i>-Catenin during Hyperammonemia. Molecular and Cellular Biology, 2019, 39, .	2.3	18
103	Vitamin D deficiency: prevalence and association with liver disease severity in pediatric nonalcoholic fatty liver disease. European Journal of Clinical Nutrition, 2020, 74, 427-435.	2.9	17
104	Diagnostic and Prognostic Significance of Complement in Patients With Alcoholâ€Associated Hepatitis. Hepatology, 2021, 73, 983-997.	7.3	17
105	Activated Protein Phosphatase 2A Disrupts Nutrient Sensing Balance Between Mechanistic Target of Rapamycin Complex 1 and Adenosine Monophosphate–Activated Protein Kinase, Causing Sarcopenia in Alcoholâ€Associated Liver Disease. Hepatology, 2021, 73, 1892-1908.	7.3	17
106	Compound Sarcopenia in Hospitalized Patients with Cirrhosis Worsens Outcomes with Increasing Age. Nutrients, 2021, 13, 659.	4.1	17
107	Metabolic reprogramming during hyperammonemia targets mitochondrial function and postmitotic senescence. JCI Insight, 2021, 6, .	5.0	17
108	Acute skeletal muscle loss in SARSâ€CoVâ€2 infection contributes to poor clinical outcomes in COVIDâ€19 patients. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 2436-2446.	7.3	17

#	Article	IF	CITATIONS
109	Alteration in body composition in the portacaval anastamosis rat is mediated by increased expression of myostatin. American Journal of Physiology - Renal Physiology, 2011, 301, G731-G738.	3.4	16
110	Design and rationale of a multicenter defeat alcoholic steatohepatitis trial: (DASH) randomized clinical trial to treat alcohol-associated hepatitis. Contemporary Clinical Trials, 2020, 96, 106094.	1.8	16
111	Alcohol Consumption Is Associated with Poor Prognosis in Obese Patients with COVID-19: A Mendelian Randomization Study Using UK Biobank. Nutrients, 2021, 13, 1592.	4.1	16
112	Clinical impact of compound sarcopenia in hospitalized older adult patients with heart failure. Journal of the American Geriatrics Society, 2021, 69, 1815-1825.	2.6	15
113	Macrophageâ€derived MLKL in alcoholâ€associated liver disease: Regulation of phagocytosis. Hepatology, 2023, 77, 902-919.	7.3	15
114	Benzodiazepines in hepatic encephalopathy: sleeping with the enemy. Gut, 1998, 42, 764-765.	12.1	14
115	Alcoholic Liver Disease on the Rise: Interorgan Cross Talk Driving Liver Injury. Alcoholism: Clinical and Experimental Research, 2017, 41, 880-882.	2.4	14
116	Hepatic encephalopathy. Current Treatment Options in Gastroenterology, 2001, 4, 517-526.	0.8	13
117	The effect of hyperammonemia on myostatin and myogenic regulatory factor gene expression in broiler embryos. Animal, 2015, 9, 992-999.	3.3	13
118	Ex-Vivo Normothermic Limb Perfusion With a Hemoglobin-Based Oxygen Carrier Perfusate. Military Medicine, 2020, 185, 110-120.	0.8	13
119	Skeletal muscle loss phenotype in cirrhosis: A nationwide analysis of hospitalized patients. Clinical Nutrition, 2020, 39, 3711-3720.	5.0	13
120	Exercise and physical activity in cirrhosis: opportunities or perils. Journal of Applied Physiology, 2020, 128, 1547-1567.	2.5	12
121	Gallstone Disease in North India. Journal of Clinical Gastroenterology, 1990, 12, 547-549.	2.2	11
122	Patient and Caregiver Attitudes and Practices of Exercise in Candidates Listed for Liver Transplantation. Digestive Diseases and Sciences, 2018, 63, 3290-3296.	2.3	10
123	Quantitative Computed Tomography Assessment of Pectoralis and Erector Spinae Muscle Area and Disease Severity in Chronic Obstructive Pulmonary Disease Referred for Lung Volume Reduction. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2021, 18, 191-200.	1.6	10
124	Integrated multiomics analysis identifies molecular landscape perturbations during hyperammonemia in skeletal muscle and myotubes. Journal of Biological Chemistry, 2021, 297, 101023.	3.4	10
125	Ammonia elicits a different myogenic response in avian and murine myotubes. In Vitro Cellular and Developmental Biology - Animal, 2017, 53, 99-110.	1.5	9
126	Plasma Krebs Cycle Intermediates in Nonalcoholic Fatty Liver Disease. Journal of Clinical Medicine, 2020, 9, 314.	2.4	9

#	Article	IF	Citations
127	Randomized placeboâ€controlled trial of losartan for pediatric NAFLD. Hepatology, 2022, 76, 429-444.	7.3	9
128	Safety of Hyaluronan 35 in Healthy Human Subjects: A Pilot Study. Nutrients, 2019, 11, 1135.	4.1	8
129	Composite Vascularized Allograft Machine Preservation: State of the Art. Current Transplantation Reports, 2019, 6, 265-276.	2.0	6
130	Cardiac expression of microRNA-7 is associated with adverse cardiac remodeling. Scientific Reports, 2021, 11, 22018.	3.3	6
131	Myogenic Response to Increasing Concentrations of Ammonia Differs between Mammalian, Avian, and Fish Species: Cell Differentiation and Genetic Study. Genes, 2020, 11, 840.	2.4	5
132	Acute Responses to Oxygen Delivery via High Flow Nasal Cannula in Patients with Severe Chronic Obstructive Pulmonary Disease—HFNC and Severe COPD. Journal of Clinical Medicine, 2021, 10, 1814.	2.4	5
133	Are Exercise Benefits in Nonalcoholic Fatty Liver Disease Due to Increased Autophagy?. Exercise and Sport Sciences Reviews, 2017, 45, 125-125.	3.0	4
134	Hepatocellular Carcinoma in Patients Without Cirrhosis: The Fibrosis Stage Distribution, Characteristics and Survival. Digestive Diseases and Sciences, 2022, 67, 2677-2687.	2.3	4
135	Ammonia Induces a Myostatin-Mediated Atrophy in Mammalian Myotubes, but Induces Hypertrophy in Avian Myotubes. Frontiers in Sustainable Food Systems, 2019, 3, .	3.9	3
136	Sonographic signs in portal hypertension: a multivariate analysis. Tropical Gastroenterology: Official Journal of the Digestive Diseases Foundation, 1996, 17, 23-9.	0.0	3
137	Role of gut bacteria in the therapy of hepatic encephalopathy with lactulose and antibiotics. Indian Journal of Gastroenterology, 2003, 22 Suppl 2, S50-3.	1.4	2
138	The Pathogenesis of Physical Frailty and Sarcopenia., 2020,, 33-53.		1
139	Reply to: "Myokines: a promising therapeutic target for hepatic encephalopathy― Journal of Hepatology, 2017, 66, 1100-1101.	3.7	O
140	Identificaiton of Nonâ€Alcoholic Steatohepatitis (NASH) Using Plasma Metabolome in Humans. FASEB Journal, 2008, 22, 1162.5.	0.5	0
141	Malnutrition and Nutrition in Liver Disease. , 2010, , 1187-1207.		0
142	Ethanol induces skeletal muscle autophagy and sarcopenia by an AMPK independent, PI3K dependent mechanism. FASEB Journal, 2013, 27, 713.8.	0.5	0
143	Nutrition and the Liver. , 2018, , 837-843.e3.		O